¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple l."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • multiple epiphyseal dysplasia
    ¹µ»À³¡Çü¼ºÀÌ»ó, ´Ù¹ß°ñ´ÜÇü¼ºÀÌ»ó
  • multiple excitation
    ´Ù¹ßÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple field irradiation
    ¿©·¯¿µ¿ªÁ¶»ç
  • multiple fission
    ¹µºÐ¿­, ´ÙÁߺп­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple infection
    º¹¼ö°¨¿°, ¿©·¯¹ø°¨¿°
  • multiple intestinal polyposis
    ´Ù¹ßÀåÆú¸³Áõ
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ, ´Ù¹ßÀåÁßøÁõ
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±Ù(À°)¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ°ÉÀ½
  • multiple infection
    ¿©·¯¹ø°¨¿°
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ
  • multiple field irradiation
    ´ÙÁ¶»ç¿µ¿ªÁ¶»ç
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
  • multiple myositis
    ´Ù¹ß±ÙÀ°¿°
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù°£´ë°æ·Ã
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple allelomorph
    º¹´ë¸³À¯ÀüÀÚ(¡­Óßí¡ë¶îîí­).
  • multiple allelomorphism
    º¹´ë¸³¼º(¡­Óßí¡àõ).
  • multiple amputation
    ´ÙºÎÀ§ Àý´Ü(ÒýÝ»êÈôîÓ¨).
  • multiple angiofibroma
    ´Ù¹ß¼º Ç÷°ü ¼¶À¯Á¾
  • multiple benign cystic epithelioma
    ´Ù¹ß¼º ¾ç¼º ³¶Á¾¼º »óÇÇÁ¾
  • multiple birth
    ´Ù»ê(Òýß§), ´ÙÅÂÃâ»ê(Òý÷Ãõóß§).
  • multiple bond
    ´ÙÁß°áÇÕ(ÒýñìÌ¿ùê).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
  • multiple budding
    ´Ù¼öÃâ¾Æ(Òýâ¦õóä´).
  • multiple cerebral sclerosis
    ¹æ»ç ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(ÒýÛ¡àõÓÞÒàÌãûùñø).
  • multiple cerebral sclerosis
    ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(Û¯ÞÒ¡­ÓÞÒàÌãûùñø)
  • multiple chain
    º¹½Ä(ÜÜãÒ)»ç½½.
  • multiple characters
  • multiple compressed tablet
    ´ÙÁß¾ÐÃàÁ¤Á¦(Òýñìäâõêïüð¥).
  • multiple congenital polyposis
    ´Ù¹ß¼º ¼±Ãµ¼º(¡­à»ô¸àõ) Æú¸³Áõ(¡­ñø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MDII Multiple Daily Insulin Injections
MEDAC Syndrome Multiple-Endocrine Deficiency Autoimmune-Candidiasis
MM Multiple Myeloma
MS   1) Mitral Stenosis
  2) Multiple Sclerosis; ´Ù¹ß¼º °æÈ­Áõ
  3) Macro...
MSLT Multiple Sleep Latency Test
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MANOVA Multiple Analysis of Variance
MAR Multiple Antibiotic Resistance
MAP Multiple Antigen Peptide
MAP Multiple Antigenic Peptide
MCS Multiple Chemical Sensitivities
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple endocrine neoplasia
    ´Ù¹ß¼º ³»ºÐºñ Á¾¾ç
  • multiple epiphyseal dysplasia
    ´Ù¹ß¼º °ñ´Ü ÀÌÇü¼ºÁõ
  • multiple epulides fissurata
    ´Ù¹ß¼º ¿­¼º Ä¡À°Á¾
  • multiple excitaiton
    ´ÙÁß ¿©±â
  • multiple factor
    ´Ù¹ß¼º ÀÎÀÚ
  • multiple fracture
    ´Ù¹ß¼º °ñÀý
  • multiple hamartoma syndrome
    ´Ù¹ß¼º °ú¿ÀÁ¾ ÁõÈıº
    ´Ù¹ß¼ºÀÌ¸ç ¸ð¹Ý ¸ð¾çÀÎ ¿Ü¹è¿±¼º, Á߹迱¼º ¹× ³»¹è¿±¼ºÀÇ ½Å»ý¹°¼º ±âÇüÀ» Ư¡À¸·Î ÇÏ´Â À¯Àüº´. ¾ó±¼ ¹× ±¸°­ Á¡¸·ÀÇ ±¸ÁøÀÌ °¡Àå Æ¯Â¡ÀûÀÎ º´º¯ÀÌ´Ù. ±× ¿ÜÀÇ º´º¯Àº ÇǺÎ, °©»ó¼±
  • multiple handicapped children
    º¹ÇÕ Àå¾Ö¾Æ
  • multiple infection
    ´Ù¹ß¼º °¨¿°
  • multiple lentigines syndrome
    ´Ù¹ß¼º ÈæÀÚ ÁõÈıº
    »ó¿°»öü¼º ¿ì¼ºÀÇ À¯Àü¼º ÁõÈıºÀ¸·Î¼­ ´Ù¹ß¼º °ËÀº »ç¸¶±Í, ¹«ÁõÈıº¼º ½ÉÀå °áÇÔ. ƯÀÌÇÑ ¾ó±¼ ¸ð¾ç, Æóµ¿¸Æ ÇùÂø, Áö°¢ ½Å°æ¼º ³­Ã», °ñ°Ý ÀÌ»ó, ¾ç¾È °Ý¸®, ¼º±â ±âÇü µîÀ» ³ªÅ¸³½´Ù.
  • multiple myeloma
    ´Ù¹ß¼º °ñ¼öÁ¾, ´Ù¹ß¼º ÇüÁú ¼¼Æ÷Á¾
    1. °ñ¼öÀÇ ¾Ç¼º ½Å»ý¹°. 2. ÇüÁú ¼¼Æ÷ Áúȯ±º Áß °¡Àå Áß¿äÇϰí ÈçÇÑ ÇüÅ·μ­ °ñ°Ý°è¿Í ¶§·Î ¿¬°ñ ºÎÀ§¿¡ ¼º¼÷ ¶Ç´Â ¹Ì¼º¼÷ ÇüÁú ¼¼Æ÷µéÀÌ ´Ù¹ß¼º Á¾±â¸¦ Çü¼ºÇÏ´Â °æ¿ìÀÌ´Ù. 3. ´Ù¹ß¼º °ñ¼öÁ¾Àº ³­Ä¡¼º ¾Ç¼º Ç÷¾× Á¾¾çÀÌ´Ù. ´Ù¸¥ Á¾¾çµé°ú ¸¶Âù°¡Áö·Î ¿øÀÎÀº ¸ð¸£¸ç ÁÖ¿ä Áõ»óÀ¸·Î´Â »ÀÀÇ ¾àÈ­, °ñÀý µîÀÌ °¡Àå ÈçÇϰí, ºóÇ÷, ½Å ºÎÀü, °¨¿° µîÀ¸·Î ³ªÅ¸³­´Ù. º´±â´Â 1, 2, 3±â·Î ³ª´©¸ç ´ë°³ 3±â¿¡ ÁÖ·Î ¹ß°ßµÇ³ª ±Ù·¡¿¡´Â °Ç°­ Áø´Ü µîÀ» ÅëÇØ Á¶±â¿¡ ¹ß°ßµÇ±âµµ ÇÑ´Ù. ´ëÁõÀûÀÎ Ä¡·á°¡ Áß¿äÇϸç Áúȯ ÀÚü¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·áÀÇ ¼ºÀûÀº ¸¸Á·½º·´Áö ¾Ê´Ù. Ä¡·á¸¦ ¹ÞÁö ¾ÊÀº °æ¿ì´Â Æò±Õ ¼ö¸íÀÌ ¼ö°³¿ù¿¡ ºÒ°úÇϰí Ä¡·áÇÑ °æ¿ìÀÇ Æò±Õ ¼ö¸íÀº 3³â Á¤µµÀ̳ª 3±â¿¡¼­´Â 1³â ³»¿ÜÀÌ´Ù. 1990³â´ë¿¡ Ä¡·á ¹æ¹ýÀÌ ¹ß´ÞÇÏ¿© ÀÎÅÍÆä·Ð°ú °ñ¼ö À̽ÄÀÌ ¼Ò°³µÇ¾ú´Ù. ÀÎÅÍÆä·ÐÀº ȯÀÚÀÇ º´ÀÌ ¸¹ÀÌ °¨¼ÒÇÏ¿© Ä¡·á¸¦ Áß´ÜÇÑ °æ¿ì Àç¹ßÀ» ´ÊÃß´Â È¿°ú°¡ °ËÁõµÇ¾ú´Ù. ȯÀÚÀÇ °ñ¼ö, ȤÀº ±ÙÀÚ¿¡´Â ¸»ÃÊÇ÷¾×ÀÇ Á¶Ç÷¸ð¼¼Æ÷¸¦ À̽ÄÇÏ°í °í¿ë·®ÀÇ Ç×¾Ï Ä¡·á¸¦ ÇÏ´Â ÀÚ°¡ ÀÌ½Ä Ä¡·á´Â ÇöÀç±îÁö Æò±Õ ¼ö¸íÀÌ 5³âÀÌ »óÀ¸·Î º¸°íµÇ¾î °ú°ÅÀÇ Ä¡·á¹ý°ú´Â ¿ùµîÇÑ Çâ»óÀ» º¸¿© Ȱ¹ßÇÑ ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖ´Ù. ÃÖ±Ù¿¡´Â ÀÚ°¡ À̽Ŀ¡¼­µµ ¾Ï ¼¼Æ÷°¡ ¾ø´Â Á¶Ç÷¸ð¼¼Æ÷¸¸À» ÃßÃâÇÏ¿© À̽ÄÇϴ ÷´ÜÀÇ Ä¡·á¹ýÀÌ ¼Ò°³µÇ°í ÀÖ¾î ¿ÏÄ¡¸¦ ÇâÇØ ÇÑ °ÉÀ½¾¿ ÁøÇàµÇ°í ÀÖ´Ù°í º¸¿©Áø´Ù. ´Ù¹ß¼º °ñ¼öÁ¾ÀÇ Áø´ÜÀº Southwest Oncology Grou
  • multiple myositis
    ´Ù¹ß ±Ù¿°, ´Ù¹ß¼º ±Ù¿°
  • multiple neurofibromatosis
    ´Ù¹ß ½Å°æ ¼¶À¯Á¾Áõ
  • multiple neuroma syndrome
    ´Ù¹ß¼º ½Å°æÁ¾ ÁõÈıº
  • multiple osteoma
    ´Ù¹ß¼º °ñÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
multiple exostosis A disturbance of enchondral bone growth in which multiple, generally benign osteochondromas of long bones appear during childhood, commonly with shortening of the radius and fibula; the ill-effects are usually mechanical but malignant change is rare; autosomal dominant inheritance.
Synonym: diaphysial aclasis, hereditary deforming chondrodystrophy, multiple exostosis, osteochondromatosis.
(05 Mar 2000)
multiple fission Division of the nucleus, simultaneously or successively, into a number of daughter nuclei, followed by division of the cell body into an equal number of parts, each containing a nucleus.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á